AllerGene AI Therapeutics

AllerGene AI Therapeutics is a biotechnology company developing innovative cell and gene therapy approaches for severe allergies, mast cell diseases, and anaphylaxis. The company is developing an investigational in vivo mRNA CAR-T platform designed to selectively target mast cells, with the goal of addressing the cellular drivers of allergic disease. AllerGene also develops AI-powered tools to support biomedical research and therapeutic development. Its work combines cell and gene therapy, mRNA technology, immunotherapy, and artificial intelligence to explore new approaches to allergic and mast cell-mediated diseases. The platform is currently in preclinical development and has not been approved to treat or prevent any disease.